April 2026 oral arguments

Decided June 30, 2026

Whether the Executive Order complies on its face with the Citizenship Clause and with 8 U.S.C. 1401(a), which codifies that Clause?

Decided June 18, 2026

Can the Rooker-Feldman doctrine, which prevents parties who lose in state courts from challenging injuries caused by state-court judgments, be triggered by a state-court decision that remains subject to further review in state court?

Decided June 4, 2026

May the SEC seek equitable disgorgement under 15 U.S.C. §§ 78u(d)(5) and (d)(7) without showing investors suffered pecuniary harm?

Decided June 4, 2026

Are provisions of the Communications Act of 1934 that govern the Federal Communications Commission’s assessment and enforcement of monetary forfeitures consistent with the Seventh Amendment and Article III?

Decided June 4, 2026

Whether the Communications Act violates the Seventh Amendment and Article III by authorizing the FCC to order the payment of monetary penalties for failing to reasonably safeguard customer data, without guaranteeing the defendant carrier a right to a jury trial.

Decided June 23, 2026

To remove a lawful permanent resident who committed an offense listed in Section 1182(a)(2) and was subsequently paroled into the United States, must the government prove that it possessed clear and convincing evidence of the offense at the time of the lawful permanent resident’s last reentry into the United States?

Decided June 25, 2026

Does the Federal Insecticide, Fungicide, and Rodenticide Act preempt a label-based failure-to-warn claim where EPA has not required the warning?

Decided June 29, 2026

Did the execution of the geofence warrant violate the Fourth Amendment?

Decided June 23, 2026

Does either the Alien Tort Statute or the Torture Victim Protection Act allow a judicially-implied private right of action for aiding and abetting?

Decided June 4, 2026

1. When a generic drug manufacturer excludes a patented use from its label, can it still be liable for inducing infringement if it calls its product a “generic version” of the brand-name drug and cites publicly available information about the brand-name drug’s sales? 2. Can a patent infringement complaint survive dismissal if it does not allege that the defendant made any statement specifically instructing or encouraging the patented use?

Decided June 25, 2026

1. Whether the judicial-review bar in the TPS statute, 8 U.S.C. 1254a(b)(5)(A), precludes respondents' APA claims? 2. If reviewable, whether respondents' APA claims nonetheless fail on the merits?